InsuLife is a Norwegian company aiming at developing and bringing the unparalleled investigational Levellor™ spray-based insulin to market. This includes the carrying out of any and all necessary product studies and authorization activities. Levellor™ will represent an international innovation and paradigm shift. Insulin in spray form has the potential to fulfill a need for people with diabetes who want to avoid needles and to take insulin in the most practical way. There is no transdermal insulin spray in the global pharmaceutical market today. InsuLife are developing a novel product with delivery of of insulin by spray-on-the-skin will be easy and efficacy is expected to be comparable to the traditional subcutaneous injections. The Future of Insulin Delivery Levellor aims to be the first transdermal spray-on Insulin. Sprayed directly onto the skin, Levellor eliminates the use of needles. The target of this breakthrough product: Eliminates multiple injections per day Room temperature stable, requiring no refrigeration Potential for better patient compliance Utilizes unmodified human insulin, a “commodity” drug product enabling cost competitiveness